Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

Atopic Dermatitis

Off-label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review

J Am Acad Dermatol.

Igelman S, Kurta AO, Sheikh U, McWilliams A, Armbrecht E, Jackson Cullison SR, Kress DW, Smith A, Castelo-Soccio L, Treat J, Boothe WD, Diaz LZ, Levy ML, Patel A, Lee LW, Fraile-Alonso MC, Antaya RJ, Shah S, Kittler N, Arkin L, Siegfried E

doi: 10.1016/j.jaad.2019.10.010.

Atopic Dermatitis

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

J Am Acad Dermatol.

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M

doi: 10.1016/j.jaad.2019.07.074.

Further Publications Dermatology

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study

Br J Dermatol

Zhao Y, Wu L, Lu Q, Gao X, Zhu X, Yao X, Li L, Li W, Ding Y, Song Z, Liu L, Dang N, Zhang C, Liu X, Gu J, Wang J, Geng S, Liu Q, Guo Y, Dong L, Su H, Bai L, O'Malley JT, Luo J, Laws E, Mannent L, Ruddy M, Amin N, Bansal A, Ota T, Wang M, Zhang J

doi: 10.1111/bjd.20690

Atopic Dermatitis

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

J Am Assoc Nurse Pract

Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M

doi: 10.1097/JXX.

Atopic Dermatitis

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

JAMA Dermatol

Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K

doi: 10.1001/jamadermatol.2021.1273

Atopic Dermatitis

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

Am J Clin Dermatol.

Frampton JE, Blair HA

doi: 10.1007/s40257-018-0370-9.

Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B

doi: 10.1016/

Atopic Dermatitis

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Br J Dermatol

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.

doi: 10.1111/bjd.20873

Related content

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Off-label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies